Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorNombre químico: 6-Maleimidohexanoyl-valyl-alanyl-(4-aminobenzyl chloride) // Sinónimos: Mal-hexanoyl-Val-Ala-PAB-Cl, MC-VA-PAB-Cl,N-((S)-1-(((S)-1-((4-(chloromethyl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide,6-Ma ileimidohexanoyl-VA-(4-aminobenzyl chloride)
from 500,00 €
Linker for Antibody-Drug-Conjugation (ADC). In contrast to the hydroxybenzyl derivative ADC1270 the chloride is able to react with tertiary amines to form a linked quarternary amine. The Val-Ala will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome the ADC payload will be released only in the cell.
Laurent Ducry (ed.), Antibody-Drug Conjugates, Methods in Molecular Biology, vol. 1045, Springer Science+Business Media, LLC 2013; https://doi.org/10.1007/978-1-62703-541-5_5.
Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates; L. R. Staben, S. G. Koenig, S. M. hear, R. Vandlen, D. Zhang, J. Chuh, S.-F. Yu, C. Ng, J. Guo, Y. Liu, A. Fourie-O’Donohue, M. Go, X. Linghu, N. L Segraves, T. Wang, J. Chen. B. Wei, G. D. L. Phillips, K. Xu, K. R. Kozak, S. Mariathasan, J. A. Flygare, T. H. Pillow; Nat. Chem. 2016; 8: 1112-1119. https://doi.org/10.1038/NCHEM.26.
Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors; L. R. Staben, S.-F. Yu, J. Chen, G. Yan, Z. Xu, G. Del Rosario, J. T. Lau, L. Liu, J. Guo, B. Zheng, J. dela Cruz-Chuh, B.-C. Lee, R. Ohri, W. Cai, H. Zhou, K. R. Kozak, K. Xu, G. D. L. Phillips, J. Lu, J. Wai, A. G. Polson, T. H. Pillow; ACS Med. Chem. Lett. 2017; 8(10): 1037-1041. https://doi.org/10.1021/acsmedchemlett.7b00243.
Highly Efficient Synthesis of a Staphylococcus aureus Targeting Payload to Enable the First Antibody-Antibiotic Conjugate; X. Linghu, N. L. Segraves, I. Abramovich, N. wong, B. Müller, N. Neubauer, S. Fantasia, S. Rieth, S. Bachmann, M. Jansen, C. G. Sowell, D. Askin, S. G. Koenig, F. Gosselin; Chem. Eur. J. 2018; 24(12): 2837-2840. https://doi.org/10.1002/chem.201705392.
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates; P. J. Burke, J. Z. Hamilton, T. A. Pires, J. R. Setter. J. H. Hunter, J. H. Cochran, A. B. Waight, K. A. Gordon, B. E. Toki, K. K. Emmerton, W. Zeng, I. J. Stone, P. D. Senter, R. P. Lyon, S. C. Jeffrey; Mol. Cancer Ther. 2016; 15(5): 938-954. https://doi.org/10.1158/1535-7163.MCT-16-0038.
Por favor envíeme más información sobre